BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$87.90 USD
+1.60 (1.85%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $87.94 +0.04 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Brokerage Reports
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 21 - 40 ( 818 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for BMRN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3 Chutes Ladders-VOXZOGO Climbs, ROCTAVIAN Falls as Launch Headwinds Persist
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-The Wedbush Monthly Check-Up: November 2023
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
RD Day: VOXZOGO Drives Growth but ROCTAVIAN Remains a "Show Me" Story
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
1st Patient Dosed with ROCTAVIAN in EU, 1yr Post-Approval; Eyes on YE Execution
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A